Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/10/2017|
|Rapid review completed||23/11/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|